Company / Cost of Revenue
Idexx Laboratories Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.6B
FY2025
5-year range
$1.3B / $1.6B
FY2021-FY2025
Trend
+8.3%
vs FY2024
Sector context
#33 of 107
Health Care
What the data says
At $1.6B, Idexx Laboratories's cost of revenue ranks #75 of 107 in the Health Care sector. Cost of Revenue has increased for 9 consecutive years, from $800M in FY2016 to $1.6B in FY2025.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +7.7%.
Increased from $1.5B to $1.6B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +6.5%
- 5-Year CAGR
- +7.7%
- 10-Year CAGR
- -
Sector benchmark
#75 of 107 in Health CareTop 69% of 107This company $1.6B Sector average $11.8B
▼
-86.0% below sector average
Key checks
Key Insights
- Idexx Laboratories's cost of revenue has grown for 9 consecutive years.
- 5-year CAGR of +7.7%, indicating consistent growth.
- In FY2025, cost of revenue increased 8.3% year-over-year.
- Ranks #33 out of 107 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +8.3% |
| FY2024 | $1.5B | +3.2% |
| FY2023 | $1.5B | +7.9% |
| FY2022 | $1.4B | +2.8% |
| FY2021 | $1.3B | +16.8% |
| FY2020 | $1.1B | +9.1% |
| FY2019 | $1.0B | +7.2% |
| FY2018 | $971.7M | +11.5% |
| FY2017 | $871.7M | +9.0% |
| FY2016 | $800.0M | +12.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026